Dimensional Fund Advisors LP Raises Position in Glaukos Co. (NYSE:GKOS)

Dimensional Fund Advisors LP grew its holdings in shares of Glaukos Co. (NYSE:GKOS - Free Report) by 9.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 312,314 shares of the medical instruments supplier's stock after acquiring an additional 26,540 shares during the quarter. Dimensional Fund Advisors LP owned 0.57% of Glaukos worth $46,828,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. IFP Advisors Inc bought a new stake in Glaukos in the fourth quarter worth $43,000. Asset Planning Inc bought a new position in Glaukos during the 4th quarter worth approximately $90,000. Picton Mahoney Asset Management purchased a new position in Glaukos in the 4th quarter worth approximately $125,000. SBI Securities Co. Ltd. bought a new stake in Glaukos in the fourth quarter valued at approximately $153,000. Finally, Smartleaf Asset Management LLC boosted its stake in shares of Glaukos by 275.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier's stock valued at $164,000 after purchasing an additional 807 shares during the period. 99.04% of the stock is currently owned by institutional investors.

Insider Activity at Glaukos

In related news, CFO Alex R. Thurman sold 1,520 shares of Glaukos stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the sale, the chief financial officer now owns 53,431 shares of the company's stock, valued at $5,708,568.04. The trade was a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Tomas Navratil sold 3,416 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares in the company, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. 6.40% of the stock is currently owned by insiders.

Glaukos Stock Down 0.9 %

GKOS stock traded down $0.81 during trading on Monday, hitting $86.80. 1,135,611 shares of the stock traded hands, compared to its average volume of 675,886. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The stock has a market cap of $4.96 billion, a price-to-earnings ratio of -30.24 and a beta of 0.88. Glaukos Co. has a 1 year low of $77.10 and a 1 year high of $163.71. The firm's 50 day moving average is $96.93 and its two-hundred day moving average is $128.49.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The company had revenue of $106.66 million during the quarter, compared to analyst estimates of $102.78 million. During the same period in the previous year, the business earned ($0.70) EPS. The firm's revenue for the quarter was up 24.6% on a year-over-year basis. On average, sell-side analysts anticipate that Glaukos Co. will post -1.08 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on GKOS. Piper Sandler lowered their price target on shares of Glaukos from $180.00 to $165.00 and set an "overweight" rating for the company in a report on Tuesday, April 15th. Mizuho dropped their target price on shares of Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a report on Wednesday, April 16th. Wells Fargo & Company downgraded Glaukos from an "overweight" rating to an "equal weight" rating and reduced their price target for the company from $160.00 to $86.00 in a report on Thursday. Stephens cut their price objective on Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday. Finally, Truist Financial restated a "buy" rating and set a $135.00 target price (down previously from $140.00) on shares of Glaukos in a report on Thursday. One research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, Glaukos currently has an average rating of "Moderate Buy" and a consensus target price of $137.62.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.